$ARVN

$7.52▲ +2.9% YTD

7 SEC 13D/G filings tracked · Last updated Oct 7, 2026

Filing History

CP $7.52▲ +2.9%Oct 7, 2026 · ThinkSabio Blog

$ARVN - Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease…

News

ARVN ▼ -4.0% - Arvinas, Inc.

CP $7.43▲ -4.0%Oct 1, 2026 · ThinkSabio Blog

$ARVN - Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congre…

News

ARVN ▼ -0.1% - Arvinas, Inc.

CP $7.50▲ -0.1%Sep 29, 2026 · ThinkSabio Blog

$ARVN - Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)…

News

ARVN ▲ +0.8% - Arvinas, Inc.

CP $7.65▲ +0.8%Sep 28, 2026 · ThinkSabio Blog

$ARVN - Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate…

News

ARVN ▼ -2.7% - Arvinas, Inc.

CP $9.32▲ -2.7%Sep 3, 2026 · ThinkSabio Blog

$ARVN - Arvinas to Participate in Upcoming Investor Conferences…

News

ARVN ▲ +0.7% - Arvinas, Inc.

CP $9.28▲ +0.7%Sep 1, 2026 · ThinkSabio Blog

$ARVN - Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)…

SEC 13D/G

ARVN - Arvinas, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks Simplified

$8.93▼ -22.21%Aug 15, 2026 · ThinkSabio Blog

$ARVN SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #ARVN Arvinas, Inc. : $8.93 Sector: Healthcare | YTD: 🔽 -22.21%…